Industry News

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentations of new pre-clinical data on the mechanism of action supporting selective targeting of single point mutations. Also, data was presented on 3 GA targeting the NLRP3 gene for the treatment of..."/>
Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Meridian Bioscience said on Monday that it has amended its agreement with Eiken Chemical Co Ltd Japan to license the latter's' LAMP' technology for the expanded areas of animal, food and water testing. The LAMP technology, developed at EIKEN in 1998, is a core technology being exploited to develop a range of products. The LAMP technology is a leading nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single..."/>
Meridian amends molecular test technology license agreement with Eiken Chemical Co to include food or water
Cumberland Pharmaceuticals reported on Monday that it has started promoting Ethyol for Injection in the US oncology market. The company said the US launch represents an important milestone in ensuring patients have the best opportunity to be treated with Ethyol, should they need it. In preparation with Ethyol's market launch, the company has completed training its sales and medical organisation, stocked the product at wholesalers serving..."/>
Cumberland Pharmaceuticals promotes Ethyol in support of oncology patients in the US
Chembio Diagnostics reported on Monday the receipt of US Department of Agriculture's USD600, 000 grant to develop a POC diagnostic test for bovine tuberculosis under the Small Business Innovation Research Program of the National Institute of Food and Agriculture. As part of the two-year grant, the company will use its patented DPP technology to undertake to develop a simple, rapid, accurate and cost-effective test for bovine TB in cattle."/>
Chembio receives USD600,000 US Department of Agriculture award to develop point-of-care diagnostic test for bovine tuberculosis
Communique from Oasmia's Annual General Meeting 2016
Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in Clinical..."/>
New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery
Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine, today announced that the first patient with incomplete AIS-B cervical spinal cord injury was successfully dosed with 10 million cells of AST-OPC1 in the SCiSTAR clinical trial at Shepherd Center in Atlanta. The company recently received FDA clearance to expand the study into this additional patient population based on the..."/>
Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population
Hill-Rom Holdings, Inc.. The combination creates the most comprehensive perinatal safety platform available, and marks a new era in obstetric solutions. Users of both the PeriGen PeriCALM ® and WatchChild..."/>
PeriGen and WatchChild Combine Forces
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the initiation of the Phase 3 IAP312 study of Zalviso ®, an investigational product candidate being developed for the management of moderate-to-severe acute pain in adult patients in a hospital setting."/>
AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain
ProNAi Therapeutics, Inc., a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an..."/>
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
ProNAi Therapeutics, Inc., a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained..."/>
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
Accuray Incorporated announced today that data from a prospective, 21 center study showed 97 percent of low- and intermediate-risk prostate cancer patients had excellent cancer control five years after receiving stereotactic body radiation therapy administered with the CyberKnife ® System. The treatment was extremely well-tolerated; serious side effects were uncommon after more than five years of follow-up."/>
Prospective, Multi-Institutional Study Shows Five Treatments with the CyberKnife® System Provide Excellent Disease Control for Prostate Cancer Patients
Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, today announces it has received Rare Pediatric Disease designation from the US Food and Drug Administration for ezutromid in the treatment of DMD. As a utrophin modulator, ezutromid has potential as a disease-modifying treatment for all patients with the fatal muscle wasting..."/>
Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
pSivida Corp., a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the appointment of Jay S. Duker, M.D, to the Company’ s Board of Directors. Duker is the Director of the New England Eye Center and Professor and Chairman of Ophthalmology at the Tufts Medical Center and the Tufts University School of Medicine.. Jay Duker is a recognized international expert in the treatment of diseases of the..."/>
PSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the appointment of President and Chief Executive Officer Dan Gladney as Chairman of the Board of Directors, effective October 14, 2016. Mark Knudson, co-founder of EnteroMedics, who will be retiring from the Board. Knudson will be Special Advisor to the CEO on..."/>
EnteroMedics Announces Appointment of Dan Gladney as Chairman of the Board of Directors
Nektar Therapeutics today announced a new clinical collaboration to evaluate Bristol-Myers Squibb’ s Opdivo with Nektar’ s investigational medicine, NKTR-214, as a potential combination treatment regimen in five tumor types and seven potential..."/>
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214
Boston Scientific and EndoChoice Holdings, Inc. today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire EndoChoice. Upon completion of the transaction, EndoChoice will become part of the Boston Scientific endoscopy business. EndoChoice develops and commercializes innovative products and services for specialists treating a wide range of..."/>
Boston Scientific to Acquire EndoChoice
AbbVie revealed on Monday that it has filed its supplemental New Drug Application for ibrutinib for the treatment of patients with marginal zone lymphoma, a slow-growing form of non-Hodgkin's lymphoma. The company added that its sNDA submission with the US Food and Drug Administration is based on data from a multi-centre, open-label Phase II PCYC-1121-CA trial assessing ibrutinib as a single-agent treatment for MZL."/>
AbbVie submits sNDA for ibrutinib (IMBRUVICA) for treating marginal zone lymphoma
Exelixis Inc announced on Monday that Julie Anne Smith has been elected to the company's board of directors, effective 22 September 2016.. Currently, Smith serves as president and chief executive officer of Raptor Pharmaceuticals, a position she has held since 2013. She joined Raptor Pharmaceuticals in 2012, beginning her tenure as executive vice president and chief operating officer."/>
Exelixis names Julie Anne Smith to board
Mylan NV faced accusations Monday that Chief Executive Heather Bresch wasn't forthright when she told Congress the drugmaker makes $100 in profit on a two-pack of its EpiPen allergy device because she didn't make clear that tax expenses had been deducted from the figure. The company disclosed in a regulatory filing Monday that profit, which Bresch provided last week during a congressional hearing about the device's skyrocketing price, factored a 37.5 percent U.S...."/>
Mylan: Epipen profits higher than Bresch told Congress [The Pittsburgh Tribune-Review]
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that an editorial addressing approaches to Category 1 testing of abuse-deterrent formulations of opioids has been published in Pain Practice. The editorial titled, "Striving for Consensus on Approaches to Category 1 Testing of..."/>
Editorial Discussing Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids Published in Pain Practice

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology571 Articles
Consumer Discretionary494 Articles
Financials323 Articles
Industrials319 Articles
Health Care290 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at